Warren Buffett Pick CBI Tumbles on Rating Downgrade

Amicus Therapeutics, Inc. (NASDAQ:FOLD), Coronado Biosciences Inc (NASDAQ:CNDO) and Receptos Inc (NASDAQ:RCPT) hit midday posting major gains this Monday. Getting a sluggish start to the week are Fate Therapeutics Inc (NASDAQ:FATE), Potash Corp. (NYSE:POT) and Chicago Bridge & Iron Company N.V. (NYSE:CBI).


Amicus, Receptos Keep on Climbing

Amicus Therapeutics, Inc. (NASDAQ:FOLD) climbed +10.96% early in the day. The biopharmaceutical company has surged +36.2% over the past week, spurred by positive trial data and stock offer pricing. It’s been a breakout year for Amicus, which has gained +229.79% year-to-date.

Coronado Biosciences Inc (NASDAQ:CNDO) got a +9.05% jump today off of CB Pharma Acquisition’s filing for an IPO. Despite today’s gain, CNDO is still down -22.81% YTD.


Receptos Inc (NASDAQ:RCPT) rallied +8.94% early in the day after announcing the completion of a previously announced underwritten public offering. The biopharmaceutical company has climbed +348.6% in 2014, and its stock is approaching a new high. Thomas Steyer’s Farallon Capital holds 350,000 RCPT shares and profited significantly on the investment.

Chicago Bridge & Iron Company Tumbles on Rating Downgrade

The share price of Fate Therapeutics Inc (NASDAQ:FATE) dipped -6.38% today. The biotech company, another Farallon Capital pick, has declined -38.61% year-to-date.

Potash Corp. (NYSE:POT) fell -5.5% today. Last week, the stock surged on news that a flood at Russia’s Uralkali could make the company the world’s largest potash producer. The company has had a rather strong year, its price climbing +4.49% since January. Billionaire Richard Chilton has had a position in POT for several years.

Chicago Bridge & Iron Company N.V. (NYSE:CBI) tumbled -5.39% early in the day after being downgraded by Goldman Sachs to a sell rating. Warren Buffett picked up a stake in the energy infrastructure company at the start of 2013 and as of the end of Q3 2014 holds 10.7 million CBI shares. David Tepper has a 1.65-million-share position in the company as well.


About the Author

Sheeraz Raza
Sheeraz is our COO (Chief - Operations), his primary duty is curating and editing of ValueWalk. He is main reason behind the rapid growth of the business. Sheeraz previously ran a taxation firm. He is an expert in technology, he has over 5.5 years of design, development and roll-out experience for SEO and SEM. - Email: sraza(at)valuewalk.com